Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Hemostasis in Subjects Undergoing Total Hip Replacement
Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Hemostasis in Subjects Undergoing Total Hip Replacement
The purpose of the study is to monitor the safety of FS VH S/D and evaluate whether FS VH S/D
 is superior to standard treatment in reducing blood loss in subjects undergoing total hip
 replacement with cement-free hip prostheses.
Inclusion Criteria:

 Each subject to be included into the study must fulfill the following inclusion criteria:

 -  Subjects receiving a cement free hip prosthesis due to coxarthrosis because of primary
 or dysplastic arthrosis grade 1 - 3 according to Crowe or rheumatoid arthritis as well
 as subjects receiving a cement free hip prosthesis due to femur head necrosis (Crowe
 classification).

 -  ASA and NSAIDs have been discontinued one week prior to surgery

 -  Written informed consent

 -  Male and female at least 19 years of age

 Exclusion Criteria:

 Subjects fulfilling the following exclusion criteria will not be recruited into the study:

 -  Impaired coagulation

 -  Previous hip surgery

 -  Acetabular roof plastic

 -  Known hypersensitivity to aprotinin or other components of the product

 -  Immunodeficiency

 -  Increased red cell production

 -  Pregnant or lactating women (positive urine or serum pregnancy test; this test is
 required of any female subject who is not post menopausal or surgically sterilized).

 -  Subjects concurrently participating in another clinical trial or having received
 another investigational drug within the last 30 days.

 Also patients with abnormal coagulation values due to anticoagulants like coumadins or
 heparin must be excluded.